Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.
Gespeichert in:
| Veröffentlicht in: | Clinical lung cancer 2024-09, Vol.25 (6), p.e262-e267 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e267 |
|---|---|
| container_issue | 6 |
| container_start_page | e262 |
| container_title | Clinical lung cancer |
| container_volume | 25 |
| creator | Muscolino, Paola Scimone, Claudia Sapuppo, Elena Micali, Vincenzo Vasta, Ignazio Santacaterina, Anna Santarpia, Mariacarmela Russo, Alessandro |
| description | •After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy. |
| doi_str_mv | 10.1016/j.cllc.2024.06.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3073713865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525730424001128</els_id><sourcerecordid>3073713865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1525-8fcafcfbb6fc5738c0b57a872defd071899345d052e1b2732f6ac6cad09a8bb43</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EoqXwAhyQj1wS_Cd2EoSEVhHdrlhRCZaz5Thj5JXjLHa2Epx4Aw59wz4JDlt65DQz1vf95JkPoZeUlJRQ-WZfGu9NyQirSiJLQvgjdE5b3hREtuRx7gUTRc1JdYaepbQnhElO2VN0xpu2qoQU5-j3GqybXXA9_gwJQsrDTz27KeCVnSFijXcfN8VlBMCbkB9utMcu4OvkRogPRpdmHWb8aQp3v26_jNr7ogPv8fYYvuFOBwPxLV7htXfjIQGeLL6aDrCAdpmzzF10mfL-OXpitU_w4r5eoK-XH3bdVbG9Xm-61bYwf5dqrNHW2L6X1oiaN4b0otZNzQawA6lp07a8EgMRDGjPas6s1EYaPZBWN31f8Qv0-sQ9xOn7EdKsRpdM_rIOMB2T4qTmNeWNFFnKTlITp5QiWHWIbtTxh6JELUGovVqCUEsQikiVg8imV_f8Yz_C8GD5d_kseHcSQN7yxkFUyTjIhxpcBDOrYXL_4_8BWsKbRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073713865</pqid></control><display><type>article</type><title>Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Muscolino, Paola ; Scimone, Claudia ; Sapuppo, Elena ; Micali, Vincenzo ; Vasta, Ignazio ; Santacaterina, Anna ; Santarpia, Mariacarmela ; Russo, Alessandro</creator><creatorcontrib>Muscolino, Paola ; Scimone, Claudia ; Sapuppo, Elena ; Micali, Vincenzo ; Vasta, Ignazio ; Santacaterina, Anna ; Santarpia, Mariacarmela ; Russo, Alessandro</creatorcontrib><description>•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.</description><identifier>ISSN: 1525-7304</identifier><identifier>ISSN: 1938-0690</identifier><identifier>EISSN: 1938-0690</identifier><identifier>DOI: 10.1016/j.cllc.2024.06.003</identifier><identifier>PMID: 38944565</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acrylamides - therapeutic use ; Aniline Compounds - therapeutic use ; Antineoplastic Agents - therapeutic use ; C797S ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Drug Resistance, Neoplasm ; EGFR ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; Gefitinib ; Gefitinib - therapeutic use ; Humans ; Indoles ; Lung Neoplasms - drug therapy ; Osimertinib resistance ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines ; Rechallenge</subject><ispartof>Clinical lung cancer, 2024-09, Vol.25 (6), p.e262-e267</ispartof><rights>2024 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1525-8fcafcfbb6fc5738c0b57a872defd071899345d052e1b2732f6ac6cad09a8bb43</cites><orcidid>0000-0002-3365-1972</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cllc.2024.06.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38944565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muscolino, Paola</creatorcontrib><creatorcontrib>Scimone, Claudia</creatorcontrib><creatorcontrib>Sapuppo, Elena</creatorcontrib><creatorcontrib>Micali, Vincenzo</creatorcontrib><creatorcontrib>Vasta, Ignazio</creatorcontrib><creatorcontrib>Santacaterina, Anna</creatorcontrib><creatorcontrib>Santarpia, Mariacarmela</creatorcontrib><creatorcontrib>Russo, Alessandro</creatorcontrib><title>Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?</title><title>Clinical lung cancer</title><addtitle>Clin Lung Cancer</addtitle><description>•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.</description><subject>Acrylamides - therapeutic use</subject><subject>Aniline Compounds - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>C797S</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Drug Resistance, Neoplasm</subject><subject>EGFR</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>Gefitinib</subject><subject>Gefitinib - therapeutic use</subject><subject>Humans</subject><subject>Indoles</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Osimertinib resistance</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines</subject><subject>Rechallenge</subject><issn>1525-7304</issn><issn>1938-0690</issn><issn>1938-0690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EoqXwAhyQj1wS_Cd2EoSEVhHdrlhRCZaz5Thj5JXjLHa2Epx4Aw59wz4JDlt65DQz1vf95JkPoZeUlJRQ-WZfGu9NyQirSiJLQvgjdE5b3hREtuRx7gUTRc1JdYaepbQnhElO2VN0xpu2qoQU5-j3GqybXXA9_gwJQsrDTz27KeCVnSFijXcfN8VlBMCbkB9utMcu4OvkRogPRpdmHWb8aQp3v26_jNr7ogPv8fYYvuFOBwPxLV7htXfjIQGeLL6aDrCAdpmzzF10mfL-OXpitU_w4r5eoK-XH3bdVbG9Xm-61bYwf5dqrNHW2L6X1oiaN4b0otZNzQawA6lp07a8EgMRDGjPas6s1EYaPZBWN31f8Qv0-sQ9xOn7EdKsRpdM_rIOMB2T4qTmNeWNFFnKTlITp5QiWHWIbtTxh6JELUGovVqCUEsQikiVg8imV_f8Yz_C8GD5d_kseHcSQN7yxkFUyTjIhxpcBDOrYXL_4_8BWsKbRw</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Muscolino, Paola</creator><creator>Scimone, Claudia</creator><creator>Sapuppo, Elena</creator><creator>Micali, Vincenzo</creator><creator>Vasta, Ignazio</creator><creator>Santacaterina, Anna</creator><creator>Santarpia, Mariacarmela</creator><creator>Russo, Alessandro</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3365-1972</orcidid></search><sort><creationdate>202409</creationdate><title>Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?</title><author>Muscolino, Paola ; Scimone, Claudia ; Sapuppo, Elena ; Micali, Vincenzo ; Vasta, Ignazio ; Santacaterina, Anna ; Santarpia, Mariacarmela ; Russo, Alessandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1525-8fcafcfbb6fc5738c0b57a872defd071899345d052e1b2732f6ac6cad09a8bb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acrylamides - therapeutic use</topic><topic>Aniline Compounds - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>C797S</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Drug Resistance, Neoplasm</topic><topic>EGFR</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>Gefitinib</topic><topic>Gefitinib - therapeutic use</topic><topic>Humans</topic><topic>Indoles</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Osimertinib resistance</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines</topic><topic>Rechallenge</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muscolino, Paola</creatorcontrib><creatorcontrib>Scimone, Claudia</creatorcontrib><creatorcontrib>Sapuppo, Elena</creatorcontrib><creatorcontrib>Micali, Vincenzo</creatorcontrib><creatorcontrib>Vasta, Ignazio</creatorcontrib><creatorcontrib>Santacaterina, Anna</creatorcontrib><creatorcontrib>Santarpia, Mariacarmela</creatorcontrib><creatorcontrib>Russo, Alessandro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muscolino, Paola</au><au>Scimone, Claudia</au><au>Sapuppo, Elena</au><au>Micali, Vincenzo</au><au>Vasta, Ignazio</au><au>Santacaterina, Anna</au><au>Santarpia, Mariacarmela</au><au>Russo, Alessandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?</atitle><jtitle>Clinical lung cancer</jtitle><addtitle>Clin Lung Cancer</addtitle><date>2024-09</date><risdate>2024</risdate><volume>25</volume><issue>6</issue><spage>e262</spage><epage>e267</epage><pages>e262-e267</pages><issn>1525-7304</issn><issn>1938-0690</issn><eissn>1938-0690</eissn><abstract>•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38944565</pmid><doi>10.1016/j.cllc.2024.06.003</doi><orcidid>https://orcid.org/0000-0002-3365-1972</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-7304 |
| ispartof | Clinical lung cancer, 2024-09, Vol.25 (6), p.e262-e267 |
| issn | 1525-7304 1938-0690 1938-0690 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3073713865 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acrylamides - therapeutic use Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use C797S Carcinoma, Non-Small-Cell Lung - drug therapy Drug Resistance, Neoplasm EGFR ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Gefitinib Gefitinib - therapeutic use Humans Indoles Lung Neoplasms - drug therapy Osimertinib resistance Protein Kinase Inhibitors - therapeutic use Pyrimidines Rechallenge |
| title | Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A51%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gefitinib%20Resensitization%20After%20a%20TKI-Free%20Interval%20in%20Osimertinib%20Resistant%20Non%E2%80%93Small-Cell%20Lung%20Cancer:%20A%20Glimpse%20of%20Hope%20in%20Time%20of%20Crisis?&rft.jtitle=Clinical%20lung%20cancer&rft.au=Muscolino,%20Paola&rft.date=2024-09&rft.volume=25&rft.issue=6&rft.spage=e262&rft.epage=e267&rft.pages=e262-e267&rft.issn=1525-7304&rft.eissn=1938-0690&rft_id=info:doi/10.1016/j.cllc.2024.06.003&rft_dat=%3Cproquest_cross%3E3073713865%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3073713865&rft_id=info:pmid/38944565&rft_els_id=S1525730424001128&rfr_iscdi=true |